Hamilton ETFs Announces Estimated Non-Cash Distributions for 2025 Tax Year
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 1 hour ago0mins
- Estimated Non-Cash Distributions: Hamilton ETFs anticipates non-cash distributions for four ETFs in 2025, with estimated amounts of $4.28, $2.62, $0.70, and $0.36 per unit, which will be automatically reinvested to maintain the number of units and net asset value unchanged.
- Tax Implications: These non-cash distributions will be treated as taxable distributions, aimed at increasing each unitholder's adjusted cost base, despite not involving cash payments, and must be completed by December 15, 2025.
- Future Update Plans: Hamilton ETFs plans to update the estimates for non-cash distributions and regular cash distribution amounts around December 22, 2025, ensuring investors receive timely information for decision-making.
- Market Position: As one of Canada's fastest-growing ETF providers, managing approximately $12 billion in assets, Hamilton ETFs is committed to offering innovative ETF products to maximize income and growth, further solidifying its influence in the financial services sector.
HUM.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUM is 293.81 USD with a low forecast of 231.00 USD and a high forecast of 341.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
8 Buy
9 Hold
1 Sell
Moderate Buy
Current: 253.020
Low
231.00
Averages
293.81
High
341.00
Current: 253.020
Low
231.00
Averages
293.81
High
341.00
Jefferies
David Windley
Hold
to
Buy
upgrade
$253 -> $313
2025-12-05
New
Reason
Jefferies
David Windley
Price Target
$253 -> $313
2025-12-05
New
upgrade
Hold
to
Buy
Reason
Jefferies analyst David Windley upgraded Humana to Buy from Hold with a price target of $313, up from $253. The firm upped the company's earnings estimates for 2026 and 2027 following an analysis of Humana's Stars diversification effort. Humana's voluntary churn and "significant" 2026 share gains should drive even higher Stars diversification than previously anticipated, the analyst tells investors in a research note.
Barclays
Andrew Mok
Equal Weight
downgrade
$245 -> $234
2025-11-25
Reason
Barclays
Andrew Mok
Price Target
$245 -> $234
2025-11-25
downgrade
Equal Weight
Reason
Barclays analyst Andrew Mok lowered the firm's price target on Humana to $234 from $245 and keeps an Equal Weight rating on the shares. If company "executes flawlessly," $14 of earnings per share next year is possible, the analyst tells investors in a research note. However, the firm says Humana's "execution risk is real." It models break-even individual Medicare Advantage margins and $11 in EPS.
Wells Fargo
Stephen Baxter
Overweight
downgrade
$347 -> $290
2025-11-10
Reason
Wells Fargo
Stephen Baxter
Price Target
$347 -> $290
2025-11-10
downgrade
Overweight
Reason
Wells Fargo analyst Stephen Baxter lowered the firm's price target on Humana to $290 from $347 and keeps an Overweight rating on the shares. The firm is also lowering estimates on refined star rating headwind given clarity on VBC / Group MA dynamics.
Truist
Hold
downgrade
$300 -> $285
2025-11-10
Reason
Truist
Price Target
$300 -> $285
2025-11-10
downgrade
Hold
Reason
Truist lowered the firm's price target on Humana to $285 from $300 and keeps a Hold rating on the shares. The firm is citing the company's Q3 results along with its "more conservative" margin assumptions, the analyst tells investors in a research note.
See All Ratings
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the key allegations in the Berman Tabacco investigation into Humana?
Why did Barclays reduce Humana's price target to $234?
How might Humana's appeal impact its Medicare Star Ratings in 2026?
What could be the long-term effects of the whistleblower complaint on Humana's stock?